A Unique Approach
to Immunology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Launched in 2015, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.
Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with severe inflammatory and autoimmune diseases.
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
Alpine’s Pipeline
We have a diverse pipeline targeting autoimmune and inflammatory diseases. For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.
Acazicolcept (ALPN-101)
Dual CD28/ICOS Costimulation Antagonist
Autoimmune Diseases
Povetacicept (ALPN-303)
Dual BAFF/APRIL B cell cytokine antagonist
Autoimmune Diseases
Alpine Immune Press Releases
- Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
- Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
- Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
